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ABSTRACT
In this study, the Nsp12–Nsp8 complex of SARS-CoV-2 was targeted with structure-based and com-
puter-aided drug design approach because of its vital role in viral replication. Sequence analysis of
RNA-dependent RNA polymerase (Nsp12) sequences from 30,366 different isolates were analysed for
possible mutations. FDA-approved and investigational drugs were screened for interaction with both
mutant and wild-type Nsp12–Nsp8 interfaces. Sequence analysis revealed that 70.42% of Nsp12
sequences showed conserved P323L mutation, located in the Nsp8 binding cleft. Compounds were
screened for interface interaction, any with XP GScores lower than 7.0 kcal/mol were considered as
possible interface inhibitors. RX-3117 (fluorocyclopentenyl cytosine) and Nebivolol had the highest
binding affinities in both mutant and wild-type enzymes, therefore they were selected and resultant
protein–ligand complexes were simulated for analysis of stability over 100ns. Although the selected
ligands had partial mobility in the binding cavity, they were not removed from the binding pocket
after 100ns. The ligand RX-3117 remained in the same position in the binding pocket of the mutant
and wild-type enzyme after 100ns MD simulation. However, the ligand Nebivolol folded and
embedded in the binding pocket of mutant Nsp12 protein. Overall, FDA-approved and investigational
drugs are able to bind to the Nsp12–Nsp8 interaction interface and prevent the formation of the
Nsp12–Nsp8 complex. Interruption of viral replication by drugs proposed in this study should be fur-
ther tested to pave the way for in vivo studies towards the treatment of COVID-19.
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Novel coronavirus disease (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in approximately 19,000,000 confirmed cases and
700,000 deaths worldwide as of 5 August 2020 (World Health
Organization, 2020a). It was announced by the WHO as a
new pandemic on 11 March 2020, with rapidly increasing
incidence of cases and deaths from all over the world (World
Health Organization, 2020b). There is no specific treatment
or drug developed against COVID-19 caused by SARS-CoV-2
currently (Wang et al., 2020). While scientists from all over
the world are working to develop various treatment options,
currently one of the fastest methods for identification of
potent drugs for COVID-19 is drug repositioning of FDA-
approved drugs, by targeting enzymes essential for the life
cycle of SARS-CoV-2 (Zhou et al., 2020). Drug repositioning
decreases cost, saves time and also decreases the risk of fail-
ure (Pushpakom et al., 2019). The efficacy of some FDA-
approved drugs against coronaviruses like severe acute
respiratory syndrome coronavirus (SARS-CoV), Middle East
respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-
2, have been tested via in silico studies (De Wilde et al.,
2014; Pillaiyar et al., 2020; Wu, Liu, et al., 2020). Recently,
repositioning of drugs like Remdesivir and methylcobalamin
has been suggested as potential inhibitory drugs against
SARS-CoV-2 (Chakrabortya, 2020; Narayanan & Nair, 2020;
Zhou et al., 2020). However, new drug studies by reposition-
ing still need to be performed until an effective drug against
SARS-CoV-2 can be found.
Viral genome replication has one of the most important
roles for SARS-CoV-2 life cycle as it polymerizes the RNA, and
makes proofreading and final capping activities by using
various viral and host proteins (Romano et al., 2020). Human
coronaviruses including SARS, MERS and SARS-CoV-2 have 16
non-structural proteins (Nsps) encoded by open reading
frames 1a and 1b (ORF 1a/1b) (Wu, Peng, et al., 2020), and
conserved Nsps play a part in several coronavirus replication
and transcription processes (Ahn et al., 2012; Chan et al.,
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2015; Perlman & Netland, 2009). Nsp12 is one of the con-
served Nsp among coronaviruses (Gorbalenya et al., 2020). It
has ‘cupped right hand’ structure with the subdomains
including a finger domain, a palm domain, a thumb domain
and a N-terminal extension domain with the total of 932
amino acids in length (Kirchdoerfer & Ward, 2019; Posthuma
et al., 2017; Ruan et al., 2020; Sexton et al., 2016). The N-ter-
minal extension domain has a nidovirus RdRp-associated
nucleotidyltransferase (NiRAN) domain and an interface
domain (Kirchdoerfer & Ward, 2019). Viral growth is associ-
ated with NiRAN domain for SARS-CoV (Romano et al., 2020).
Studies suggest that role of NiRAN domain for SARS-CoV-2
Nsp12 exhibits the structural property of kinase-like folds
(Kirchdoerfer & Ward, 2019; Romano et al., 2020). Nsp12 is
also part of the C-terminal domain of coronavirus replica-
tion/transcription complex, this is an RNA-dependent RNA
polymerase (RdRb) domain which shows weak primer-
dependent RNA synthesis activity without co-factors (te
Velthuis et al., 2010). Nsp12 is a vital enzyme that functions
as an RdRp (Perlman & Netland, 2009; Wu, Liu, et al., 2020),
in addition, Nsp8 is also found to be associated with RdRp
(te Velthuis et al., 2012). The role of Nsp8 in RdRp is defined
as a primase for RNA synthesis (Perlman & Netland, 2009; te
Velthuis et al., 2012). Structural analysis of Nsp8 revealed
that it complexes with Nsp7 during their primer-dependent
RdRp activity, in the study a Nsp7–Nsp8 complex of SARS-
CoV protein structure is identified in 3D with 2.4 Å resolution
(Subissi et al., 2014; te Velthuis et al., 2012; Zhai et al., 2005).
Moreover, Nsp7 and Nsp8 are identified as co-factors of
SARS-CoV Nsp12 that stimulate polymerase activity of Nsp12
by forming a complex, which is vital for SARS-CoV replication
(Kirchdoerfer & Ward, 2019; Subissi et al., 2014). Nsp12 binds
Nsp7 and Nsp8 and includes a kinase-like fold for SARS-CoV
(Kirchdoerfer & Ward, 2019). The Nsp12–Nsp7–Nsp8 complex
and its stoichiometry are confirmed for SARS-CoV along with
some of their surface interactions (Kirchdoerfer & Ward,
2019). There are 96.35%, 98.8% and 97.5% similarities among
Nsp12, Nsp7 and Nsp8 of SARS-CoV and SARS-CoV-2,
respectively (Ruan et al., 2020). The Nsp12–Nsp7–Nsp8 com-
plex is targeted for SARS-CoV inhibition studies and also tar-
geted for SARS-CoV-2 (Ruan et al., 2020; Yin et al., 2020). The
structure of Nsp12–Nsp7–Nsp8 along with the structure of
an RdRp activity inhibitor Remdesivir is also studied for
SARS-CoV-2 (Yin et al., 2020).
In this study, FDA-approved and investigational drugs
were screened with wild-type and mutant SARS-CoV-2
Nsp12–Nsp8 interfaces, prioritizing high-affinity drugs, then
complexes were approved by molecular dynamics (MD) sim-
ulations for their stabilities.
2. Materials and methods
2.1. Sequence analysis
SARS-CoV-2 reference genome sequence (NC_045512.2) (Wu,
Peng, et al., 2020) was obtained from GenBank for this
research (Benson et al., 2003), and all other SARS-CoV-2 iso-
lated genome sequences with high coverage were
downloaded from GISAID EpiCoV (https://www.epicov.org/)
for comparative analysis.
In this study, the whole genome sequences of 30,366
SARS-CoV-2 isolates were aligned by Python language-based
software ODOTool, which was developed as a strategy-based
multiple sequence alignment tool and was previously tested
for variation detection among SARS-CoV-2 genomes (Ugurel
et al., 2020). The genotype differences between isolated
genomes of SARS-CoV-2 were defined visually using the
JalView v2.10.5 alignment viewer (Waterhouse et al., 2009).
Mutations that caused amino acid exchanges in essential
genes for the life cycle of SARS-CoV-2 and present in more
than 50% of the isolate genome sequences were identified.
Reverse analysis has shown that two of the most common
mutations are on the Nsp12 region and near the active site
of RNA polymerase. Thus, this enzyme was designated as the
target protein in this study. Sequences of SARS-CoV-2 refer-
ence Nsp12 amino acid sequence were collected from
GenBank database and the nucleotide sequence mutant type
was translated to protein sequence by ExPASY Translate tool
(Gasteiger et al., 2003) using standard codon table (Peabody,
1989). Nsp12 wild-type protein sequences (Wuhan-Hu-1:
YP_009725307.1) and the translated sequence of first mutant
isolate (EPI_ISL_418218) were aligned using the European
Bioinformatics Institute (EMBL-EBI) MUSCLE multiple sequence
alignment tool (http://www.ebi.ac.uk/Tools/msa/muscle) (Edgar,
2004) to conduct multiple protein sequence analysis.
2.2. Virtual high-throughput screening of approved and
investigational drugs
Structures of FDA-approved and investigational drugs were
retrieved from the ZINC DB (Sterling & Irwin, 2015) and
Pubchem/ClinicialTrials sources. Drug structures were pre-
pared by LigPrep (LigPrep, Schr€odinger, LLC, New York, NY,
2020) at neutral pH. SARS-CoV-2 RNA-dependent RNA poly-
merase (Nsp12) Cryo-EM structure with 2.90 Å resolution was
obtained from the RCSB PDB (https://www.rcsb.org) with
accession number of 6M71. Adding hydrogens, filling missing
side chains, protonation at neutral pH and 0.5 Å restraint
minimization was conducted by Protein Preparation Wizard
(Protein Preparation Wizard, Schr€odinger, LLC, New York, NY,
2020) from Maestro (Maestro, Schr€odinger, LLC, New York,
NY, 2020). Mutation (P323L) of the wild-type Nsp12 protein
was created in Maestro program and mutant structure was
prepared by following the same procedure as wild-type. The
docking site, characterized as the Nsp12–Nsp8 interaction
site, was set up using the Receptor Grid Generation Panel in
Maestro. Virtual screening and molecular docking of drugs
were carried out in the interaction interface by following
Glide ‘Virtual Screening Workflow’ (Glide, Schr€odinger, LLC,
New York, NY, 2020) (Friesner et al., 2004; Halgren et al.,
2004). Prime was used for MM-GBSA binding energy calcula-
tion (Jacobson et al., 2004) (Prime, Schr€odinger, LLC, New
York, NY, 2020) of the best poses selected based on XP
GScores. Druggability of the Nsp12–Nsp8 interface was
assessed by DogSiteScorer Server (Volkamer et al., 2012)
from ProteinsPlus web portal (https://proteins.plus/). Nsp12/
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Nsp8 complex interface residue interactions were assessed
by the PDBePISA server (https://www.ebi.ac.uk/pdbe/pisa/pis-
tart.html) (Krissinel & Henrick, 2007). ADME properties of RX-
3117 were identified by using SwissADME (http://www.swis-
sadme.ch/index.php) (Daina et al., 2017).
2.3. Molecular dynamics simulations
The charge parameters for all of the bonds, angles, dihedrals
and atom types in the system of RX-3117 and Nebivolol
were assigned using AM1-BCC atomic charge (Jakalian et al.,
2002) and general AMBER force field (GAFF) parameters
(Wang et al., 2004) via Antechamber (Wang et al., 2006). For
the starting simulation, the topology and coordinate files of
complexes were prepared using AMBER14 tLeap. A truncated
octahedron box 5 Å in size was created in a periodic box of
TIP3P water (Mark & Nilsson, 2001). The systems were neu-
tralized by adding Cl and Naþ counter ions using a
Coulombic potential on a grid. Energy minimization was per-
formed to reduce bad interactions and clashes in the com-
plexes before starting the simulation. The energy
minimization was started with 10,000 cycles of steepest des-
cent (Fletcher & Powell, 1963) and switch on conjugate gra-
dient algorithms for 90,000 steps (Møller, 1993). Steepest
descent algorithm quickly eliminates severe clashes and bad
interactions. This is followed by conjugate gradient algo-
rithms, this is more effective and slower at reaching an
energy minimum. The AMBER ff14SB (Maier et al., 2015) force
field was used for all simulations. The minimized systems
were heated slowly from 10 K to 300 K with constant volume
and pressure using Langevin thermostat (Davidchack et al.,
2009) with a collision frequency of c¼ 10.0 ps1 for during
200ps with 1 femtosecond steps. The complexes of RX-3117/
Nsp12 wild-type, Nebivolol/Nsp12 wild-type, RX-3117/Nsp12
mutant, Nebivolol/Nsp12 mutant were simulated for 100 ns
with a time step of 2 fs and hydrogen atoms constrained
using the SHAKE algorithm (Ryckaert et al., 1977) was applied
to restrain all atoms during dynamics run. The temperature
during production runs was controlled using Berendsen
weak-coupling algorithm (Berendsen et al., 1984). The coordi-
nates of the system were written every 10 ps during 100 ns
MD simulation. The simulation results were evaluated using
the root mean square deviation (RMSD) and b-factor plot
using CPPTRAJ (Roe & Cheatham, 2013) from MD simulation
trajectory over 100 ns for complexes. Schr€odinger Maestro
(Maestro, Schr€odinger, LLC, New York, NY, 2020) was used in
2D ligand–protein interaction analysis and PyMOL Molecular
Graphics System (The PyMol molecular graphics system, ver-
sion 2.0. Schr€odinger, LLC, New York, NY, 2017) was used in
3D superimposition representations.
3. Results and discussion
3.1. Sequence analysis
About 30,366 genome sequences isolated from all around
the world were downloaded from either NCBI or GISAID on
20 May 2020 and deposited in a database as reported in one
of our studies (Ugurel et al., 2020). These data were further
analysed towards the repositioning of FDA-approved and
investigational drugs against SARS-CoV-2.
The SARS-CoV-2 genome consists of 11 gene regions in
total, named: ORF1ab, S, ORF3a, E, M, ORF6, ORF7a, ORF7b,
ORF8, N and ORF10 in reference genome (NC_045512.2) (Wu,
Peng, et al., 2020). Although there are many studies concern-
ing variations across whole SARS–CoV-2 genome, few of
them showed the structural impact on proteins (Gao et al.,
2020; Kirchdoerfer & Ward, 2019; Shannon et al., 2020). In
our study, we focused on the Nsp12 variations that alter the
codon sequence and cause amino acid exchanges on the
protein sequence. Three variations were found on the gene
sequence encoding Nsp12: C14408T (first reported by
Pachetti et al., 2020), C14805T and C15324T. These were pre-
sent in all 30,366 isolates at frequencies of 70.42%, 10.01%
and 2.4%, respectively (Ugurel et al., 2020). Only C14408T
variations caused amino acid exchange (P323L) on Nsp12 of
SARS-CoV-2, shown in Figure 1. Studies on SARS-CoV have
shown that Nsp12 is a vital protein for replication and patho-
genesis and also a potential target for antiviral development
studies (Perlman & Netland, 2009; Wu, Liu, et al., 2020; Yin
et al., 2020). Therefore, in this study, the effects of this amino
acid exchange on the Nsp12 was further evaluated by struc-
tural studies to determine whether Nsp12 with and without
this specific mutation in SARS-CoV-2 could possibly be tar-
geted by the repositioning of the FDA-approved and investi-
gational drugs to possibly cure COVID-19 infections.
3.2. Virtual high-throughput screening of approved and
investigational drugs
A drug library containing both FDA-approved and investiga-
tional drugs currently in clinical trials was screened for
potential interaction within the Nsp12–Nsp8 interface region.
Mutation of P323L on Nsp12 was found near to the inter-
action interface where Nsp8 protein binds and residues
between 100 and 124 of Nsp8 forms an a-helix-loop-a-helix
structure in the interaction site (Figure 2). Furthermore,
based on PDBePISA interface results, P323 forms H bond
with Asn118 of Nsp8 structure. Previous studies on SARS-CoV
Nsp12/Nsp8 complexes showed that mutations of D99A,
P116A, P183A, R190A in Nsp8 caused a decrease in primer
extension and de novo polymerase activities (Subissi et al.,
2014). The decrease in enzymatic activity was explained by
the loss of Nsp12–Nsp8 interaction due to mutations in these
critical and essential interface residues (Subissi et al., 2014).
For these reasons, studies should be addressed in order to
reveal the impact of P323L mutation on Nsp12–drug interac-
tions and Nsp12/Nsp8 complex formation. Therefore, the
Nsp12–Nsp8 interaction cleft where the P323L mutation was
found is a significant region for docking of drugs which aim
to dissect the Nsp12–Nsp8 interaction. According to the
DogSiteScorer server results, both wild-type and mutant
Nsp12 structures had one of the highest drug (0.83) and sim-
ple (0.44 and 0.42 for the wild-type and mutant, respectively)
scores for the Nsp8 interaction pocket when compared with
the other site on the Nsp12 enzyme. This also emphasizes
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the significance and the vulnerability of the Nsp12–Nsp8
interaction interface which forms a groove and allows small
chemicals to bind.
Based on virtual high-throughput screening of FDA-
approved and investigational drugs on wild-type and mutant
Nsp12 protein, drugs with XP GScores lower than 7.0 kcal/
mol was evaluated as possible inhibitors (Tables 1 and 2).
All drugs occupied the interface pocket where Nsp8 pro-
tein binds. The pocket itself was surrounded mainly by
hydrophobic residues including Valine, Leucine,
Phenylalanine, Alanine, Tyrosine and Proline. Nebivolol, RX-
3117 (fluorocyclopentenyl cytosine), Fenoterol and
Glucocorticoid interacted with both wild-type and mutant
Nsp12 structures. The common residues interacting with the
most drugs were found to be Thr324, Phe326, Pro328 and
Val330, which also interacted with the Nsp8 protein (Figure
3). Only Fenoterol was shown to form H bond with the
Pro323 residue in wild-type Nsp12 structure. Also, Fenoterol
made H bonds with Leu270, Phe326 and Val330 in both
structures. Moreover, Nebivolol made H bonds with Thr324,
Phe 326 and Pro328 of both mutant and wild-type proteins.
However, H bonding interaction of Nebivolol with Val330 has
been seen in only mutant Nsp12 structure. RX-3117 made a
p–p stacking interaction with Tyr272 of wild-type Nsp12.
Additionally, RX-3117 interacted with Leu270, Thr324,
Pro328, Val330, and Leu270, Phe326, Thr324, Val330 of wild-
type and mutant Nsp12 structures, respectively. Docking pos-
ition of the Glucocorticoids was nearly same in both struc-
tures and made H bond with the same residues including
Thr324 and Pro328. When comparing these four drugs,
Nebivolol had the lowest MM-GBSA dG binding energy and
therefore was the most leading drug in the pocket based on
the docking results. Nebivolol is a b1-adrenoreceptor antag-
onist and carries highly selective properties, it is generally
used for the treatment of hypertension patients (Giles et al.,
2017; Marketou et al., 2017; Moen & Wagstaff, 2006). To the
best of our knowledge, any antiviral effects of Nebivolol
have not been reported yet. On the other hand, RX-3117 (flu-
orocyclopentenyl cytosine) is a fluorocyclopentenyl cytosine
derivative which is in phase 2 research for advanced bladder
cancer and pancreatic cancer. RX-3117 was designed from
cytosine analogues that were shown to be active against
both DNA and RNA viruses including HIV, West Nile virus,
HSV-1 and cytomegalovirus (Choi et al., 2012; Marquez et al.,
1988; Song et al., 2001). ADME properties of the investiga-
tional compound RX-3117 were analysed by SwissADME
(http://www.swissadme.ch/index.php) (Daina et al., 2017).
ADME results showed that molecular weight of RX-3117 is
257.22 g/mol, topological polar surface area is 121.60 Å2,
number of rotatable bonds is 2, number of hydrogen bond
donors is 4, number of hydrogen bond acceptors is 6, Log
Po/w (predicted octanol/water partition coefficient) is 1.29,
LogS, (predicted aqueous solubility) is 0.01, Gastrointestinal
absorption is high, Log Kp (skin permeation) is 9.74 cm/s,
Lipinski violations is zero. These results were found to appro-
priate for Lipinski’s rule of five and Veber’s rule (Lipinski,
2004; Veber et al., 2002), therefore the compound could be
identified a drug-like compound.
Fenoterol is a 4-hydroxyphenyl derivative of metaprotere-
nol and therefore the drug is chemically similar to orciprena-
line. The compound is a b2-adrenoceptor antagonist used
for the treatment of asthma, bronchiolitis and other respira-
tory diseases (Heel et al., 1978; Svedmyr, 1985). Although
fenoterol might cause some adverse effects based on drug
doses (Wong et al., 1990), the drug was applied for asthma
treatment (Heel et al., 1978; Svedmyr, 1985). Glucocorticoids
belong to the group of steroid hormones and are clinically
used based on anti-inflammatory, immunosuppressive and
Figure 1. Alignment of Nsp12 amino acid sequences from isolates of SARS-CoV-2; wild-type: Wuhan-Hu-1 (YP_009725307.1) and mutant isolate from Lombardy,
Italy (EPI_ISL_412973).
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anti-allergic properties (Jiang et al., 2015). Glucocorticoids
also decrease inflammation of the airway and are therefore
used for the treatment of respiratory diseases like asthma
(Thomas et al., 2014; Wood & Barnes, 1995). However, this
hormone increases the infection rate of respiratory viruses
and an in vitro study showed that additional therapy would
be necessary for this treatment (Thomas et al., 2014).
Other than the drugs which were found to be interacting
with both wild-type and mutant structures, tetrahydrouridine,
dobutamine and saquinavir were found to interact only with
the wild-type Nsp12 residues including Thr324, Phe326,
Pro328, Val330 and Ser664 and had the best XP GScores
among others. Tetrahydrouridine is a competitive cytidine
deaminase inhibitor and was analysed for treatment of sickle
Figure 2. Cartoon view of the Nsp12–Nsp8 interaction interface in wild-type (a and b) and mutant structures (d and e). Surface view of the wild-type (c) and
mutant (f) Nsp12 with Nsp8 structure. Leu323 and Pro323 are shown as red stick structures.
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cell disease and some types of cancers due to the com-
pound’s effect in gene regulation (Desimone et al., 1985;
Funamizu et al., 2012; Molokie et al., 2017). In addition, it
was observed that tetrahydrouridine had an enhanced anti-
viral effect on Herpes Simplex Virus (North & Mathews,
1981). Saquinavir is an antiretroviral protease inhibitor that is
an aspartic acid derivative and a FDA-approved drug used in
the treatment of HIV (National Center for Biotechnology
Information, 2020a). Saquinavir has been proposed for the
inhibition of SARS-CoV-2 Nsp14 (Liu et al., 2020),
Nsp12–Nsp7–Nsp8 (Ruan et al., 2020) and S protein, RdRp
(nsp12 and nsp8), exonuclease (nsp14), 20-O methyltransfer-
ase (nsp16), helicase (nsp13) and Nsp10 (Xu et al., 2020).
Dobutamine is a synthetic catecholamine and FDA-approved
direct-acting inotropic agent (National Center for
Biotechnology Information, 2020b). The antiviral properties of
dobutamine were screened in silico for the SARS-CoV-2 main
protease (Farag et al., 2018) and for the nucleocapsid (N)
protein of porcine epidemic diarrhoea virus which belongs
to Coronaviridae family (Deejai et al., 2017). In mutant Nsp12,
Canagliflozin had the best XP GScore when compared with
other drugs in mutant Nsp12–Nsp8 interaction interfaces and
interacted with Val330 in this region. Canagliflozin was
approved by the FDA in 2013 and is used in the treatment
of type II diabetes. This drug is a C-glycosyl derivative com-
pound and acts as a sodium-glucose transport protein sub-
type 2 (SGLT2) inhibitor (Kaushal et al., 2014). Muscle loss is
common in patients with type II diabetes, therefore
Table 1. High-throughput virtual screening results on the Nsp12–Nsp8 interaction interface.
Drug name Glide emodel XP GScore XP HBond XP LipophilicEvdW XP Electro MM-GBSA dG bind
Wild-type Nsp12
Tetrahydrouridine –37.733 –8.41 –4.02 –1.461 –1.128 –38.08
Dobutamine –55.552 –8.213 –2.33 –4.263 –1.233 –56.45
Saquinavir –87.088 –7.887 –1.906 –5.192 –1.058 –60.94
Nebivolol –57.774 –7.699 –1.625 –4.719 –1.057 –55.64
RX-3117 –47.046 –7.386 –2.446 –2.149 –0.877 –33.16
TG100-115 –55.208 –7.307 –1.373 –3.175 –0.62 –35.72
NOP-1A –59.667 –7.264 –1.33 –3.709 –0.997 –30.27
Fenoterol –53.694 –7.101 –2.109 –3.281 –1.385 –41.11
Glucocorticoid –61.155 –7.094 –2.105 –4.191 –1.059 –53.11
Thiarabine –46.843 –7.088 –2.36 –1.837 –0.969 –38.86
Mutant Nsp12
Canagliflozin –57.008 –7.744 –2.524 –4.092 –0.806 –50.38
RX-3117 –41.285 –7.635 –2.672 –2.12 –0.957 –33.84
Epicatechin –45.364 –7.628 –3.18 –3.361 –0.679 –32.36
Nebivolol –55.228 –7.481 –1.625 –4.342 –1.266 –63.12
Ipragliflozin –50.351 –7.459 –3.176 –3.54 –0.945 –19.35
Glucocorticoid –65.488 –7.422 –2.105 –4.327 –1.108 –54.85
Secondary metabolite of Morus bark –46.566 –7.21 –3.427 –2.511 –0.925 –29.91
Fenoterol –56.128 –7.041 –1.612 –3.769 –0.88 –34.16
Drugs interact in both structures are shown in bold.
Table 2. Drug list with functional properties and current states.
Drug name PubChem/ZINC ID Function Current state




Nebivolol 71149993 b-1 adrenergic receptor antagonist.
Treatment for hypertension
Approved (FDA)
Ipragliflozin 10453870 Anti-diabetic (Type-2) Investigational,
Approved in Japan and Russia
Fenoterol 3343 Adrenergic b-2 agonist.
Treatment for respiratory diseases
Investigational,
Approved









TG100-115 10427712 PI 3-kinase inhibitor
Treatment in myocardial infarction
Investigational
Phase I–II
Secondary metabolite of Morus bark 5,42,22,687 N/A Investigational






Canagliflozin 24812758 Inhibitor of sodium-glucose





11242315 Anti-cancer activity Investigational
Phase I–II
Saquinavir ZINC000029416466 HIV protease inhibitor Approved
Dobutamine ZINC000000057278 Adrenergic and dopaminergic agent
Inotropic agent
Approved
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Canagliflozin has been found to have a positive effect on the
cardiovascular system in clinical trials in the following years.
Canagliflozin has been started to be used for preventing
muscle loss with FDA approval in 2018 (Jakher et al., 2019),
to best of our knowledge there are no publications on the
antiviral effects of Canagliflozin in the literature yet. In add-
ition to Canagliflozin, Epicatechin (a natural phenol),
Ipragliflozin (sodium-glucose cotransporter-2 inhibitor) and a
secondary metabolite of Morus bark (PubChem ID 54222687)
were also found to interact only with the mutant
Nsp12–Nsp8 interaction cleft and interacted pocket residues
including Phe326, Pro328 and Val330.
3.3. Molecular dynamics simulations
Structural dynamics of protein structures and mobility analysis
is a crucial step in molecular dynamic methods and has an
important role in determining structure-function relationships
in proteins. For these analyses, the RMSD and root mean
square fluctuations (RMSF) of the structures were calculated
during the MD simulation (Martınez, 2015). Two ligands which
have the lowest binding energy in both proteins were selected
from the library and docked to wild and mutant (P323L) forms
of Nsp12 protein. The complexes (RX-3117/Nsp12 wild-type,
Nebivolol/Nsp12 wild-type, RX-3117/Nsp12 mutant, Nebivolol/
Nsp12 mutant) were simulated for 100ns using MD methods
in order to analyse the structural mobility of these complexes
and observe any differences between both structures. For this
purpose, the simulation trajectories were processed, and the
RMSD and atomic fluctuation (b-factors) of complexes were
plotted (Figure 4). The average deviation of RX-3117/Nsp12
wild-type and Nebivolol/Nsp12 wild-type complexes during
100ns were calculated as 2.44Å and 2.28Å, respectively.
Likewise, the average deviation of RX-3117/Nsp12 mutant and
Nebivolol/Nsp12 mutant complexes during 100ns was calcu-
lated as 2.29Å and 2.51Å, respectively.
Figure 3. Docking views of Nebivolol, RX-3117, glucocorticoid and Fenoterol in the Nsp12–Nsp8 interaction interface of wild-type and mutant structures.
Figure 4. (a) Root mean square deviations (RMSD) of all Ca backbone carbon atoms for Nsp12–ligand complexes. (b) Per residue atomic fluctuations (b-factors) of
the Ca backbone carbon atoms for Nsp12–ligand complexes (RX-3117/Nsp12 wild-type complex: red, Nebivolol/Nsp12 wild-type complex: green, RX-3117/Nsp12
mutant complex: blue, Nebivolol/Nsp12 mutant complex: pink).
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Complexes without the Nebivolol/Nsp12 mutant complex
structurally stabilized after about 20 ns. The deviation of
Nebivolol/Nsp12 mutant complex increased dramatically after
20 ns but reached equilibrium after 50 ns. Also, the deviation
of RX-3117/Nsp12 mutant complex increased after 90 ns and
began to equilibrate again. The calculated average deviation
of this complex is the lowest compared to other complexes
as 2.29 Å, and the 3D structure is analysed to determine why
this occurs after the simulation at 90 ns (Figure 4(a)). This
graph demonstrates whether the compounds that are
docked to proteins remain in the binding site and their bind-
ing positions. In general, it can be concluded that all com-
plexes are stable for 100 ns, given the initial coordinates. The
b-factor plots refer to the average displacement of the Ca
Figure 5. Two-dimensional representation of protein–ligand interactions. (a) RX-3117/Nsp12 wild-type complex in the initial position, (b) RX-3117/Nsp12 wild-type
complex after 100 ns MD simulation, (c) Nebivolol/Nsp12 wild-type complex in the initial position, (d) Nebivolol/Nsp12 wild-type complex after 100 ns
MD simulation.
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backbone carbon atom of each residue according to the ini-
tial structure of a particular atom. Generally, b-factors calcu-
lated from X-ray experiments are also called temperature
factors (Bornot et al., 2011). These values obtained in this
study were calculated from the RMSF values from molecular
dynamic simulations (Figure 4(b)). The highest fluctuation in
the region between residues 268–275 was observed in the
Nebivolol/Nsp12 wild-type complex. The ligand Nebivolol is a
larger compound than the other ligands and therefore
caused greater change in the cavity. Since the region
between residues 268–275 did not form a secondary struc-
ture, Nebivolol could be easily displaced. It was observed
that local fluctuations were higher in both the wild-type and
mutant protein to which Nebivolol was bound (Figure 4(b)).
RX-3117 was docked to the hydrophobic cavity of the
Nsp12 wild-type protein using molecular docking methods
(Figure 5(a)). The ligand formed two hydrogen bonds with
Val330 as well as a hydrogen bond with both Thr-324 and
Pro-328 after 100 ns simulation, and the first position of RX-
3117 remained stable (Figure 5(b)). However, the ligand lost
Figure 6. Two-dimensional representation of protein–ligand interactions. (a) RX-3117/Nsp12 mutant complex in the initial position, (b) RX-3117/Nsp12 mutant
complex after 100 ns MD simulation, (c) Nebivolol/Nsp12 mutant complex in the initial position, (d) Nebivolol/Nsp12 mutant complex after 100 ns MD simulation.
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the hydrogen bond with Leu270 and moved closer to the
hydrophobic pocket. Nebivolol was also placed in the hydro-
phobic cavity using molecular docking methods (Figure 5(c)).
After 100 ns simulation, it formed hydrogen bonds with
Thr324 and also expanded the hydrophobic cavity by push-
ing the region between the residues 268–275 outwards
(Figure 5(d)). Therefore, the ligand had lost hydrogen bonds
with Pro328 and Phe326. It was revealed that both ligands
were stable, forming hydrogen bonds in the hydrophobic
cavity in Nsp12 wild-type protein after simulation of 100 ns
MD simulation.
The mutation in the Nsp12 protein converted Proline-323
to Leucine, and this mutation was located inside the hydro-
phobic cavity in the ligand-binding region. RX-3117 was
docked to the hydrophobic cavity using molecular docking
methods, it did not interact with the Leu323 and was
entirely located in the cavity (Figure 6(a)). After 100 ns MD
simulation, the ligand formed hydrogen bonds with Thr324
(a polar residue) but Val330 and Leu323 did not interact with
the ligand due to its location inside the cavity (Figure 6(b)).
Besides, the hydrogen bond with Leu270 and Phe326 was
not preserved after 100 ns. Likewise, Nebivolol was docked
to the same cavity by molecular docking methods (Figure
6(c)). Nebivolol formed a hydrogen bond with Thr324 and
Pro328 and remained stable in the binding position
(Figure 6(d)).
The effect of the mutation on Nsp12 protein 3D structure
and ligand binding sites was investigated in terms of
dynamic behaviour of the mutant protein with respect to the
wild-type protein. Proline, which is located at position 323 in
the wild-type Nsp12 protein, has a different cyclic structure
compared to other amino acids. The side chain is bound to
the protein backbone twice and therefore there is no alpha
hydrogen that can form a hydrogen bond in the structure.
Therefore, secondary structures in most proteins do not
involve proline, and proline limits alpha-helix structures
(Lehninger, 2004). Leucine in the mutant Nsp12 protein has
an aliphatic side chain and is a hydrophobic residue. They
Figure 7. Three-dimensional representation of protein–ligand interactions. (a) RX-3117/Nsp12 wild-type (shown in white) and mutant (shown in red) complexes,
(b) Nebivolol/Nsp12 wild-type (shown in white) and mutant (shown in red) complexes.
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are generally located within alpha-helix secondary structures
in the hydrophobic cavities (Betts & Russell, 2003).
The positions of the ligands after 100 ns MD simulation
are given in comparison with the wild-type and mutant
Nsp12 protein. RX-3117 maintained its position in both pro-
teins, but the secondary structure of mutated region was
changed. For the reasons described above, since there was a
Leucine instead of Proline in the hydrophobic pocket in the
mutant Nsp12 protein, the boundary of the a-helix second-
ary structure had disappeared and the structure had become
primary (Figure 7(a)). The position of Nebivolol after 100 ns
MD simulation was analysed comparatively in Nsp12 wild-
type and mutant protein. Nebivolol was docked to Nsp12
wild-type protein and remained almost constant after 100 ns
MD simulation. But the ligand bound to the cavity and was
buried in the mutant Nsp12 protein. The compound was
twisted from the amino group in the middle of the backbone
and became fixed in the hydrophobic cavity (Figure 7(b)).
4. Conclusion
RNA-dependent RNA polymerase (Nsp12) is the RNA replica-
tion machinery of SARS-CoV-2 virus which enhances the rep-
lication efficiency by interplaying with co-factors like Nsp8.
Sequence analysis revealed that about 70.42% (Ugurel et al.,
2020) of Nsp12 sequences bear conserved P323L mutation in
the cleft where Nsp8 binds. Herein, we have targeted to the
Nsp12–Nsp8 interaction interface by using FDA-approved
and investigational drug libraries. As a result, two drugs, RX-
3117 (fluorocyclopentenyl cytosine) and Nebivolol, were pri-
oritized as possible interaction interface binders based on
both molecular docking and simulation analysis. Further
in vitro and in vivo experiments should be performed in
order to reveal these interactions.
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